Radiotheranostics Market Size & Growth Forecast 2027–2036, By Segments (Approach, Radioisotope, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Radiotheranostics Market size stood at USD 13.6 billion in 2026 and is predicted to grow at a 9.03% CAGR from 2027 to 2036, surpassing USD 32.28 billion by 2036. The industry revenue for 2027 is estimated at USD 14.63 billion.
Get more details on this report
Request Free Sample ReportRadiotheranostics Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 54.23% share in 2026, supported by advanced nuclear medicine infrastructure, established clinical workflows, and strong industry participation driving adoption and commercialization.
- Europe is projected to grow at a 14.9% CAGR as precision oncology adoption increases and hospitals expand the use of integrated molecular imaging and targeted therapeutic workflows.
Segment Momentum
- Targeted Therapeutic held a 64.43% share in 2026 because it combines molecular targeting with treatment delivery, supporting precise, patient-specific care and expanding use within established clinical workflows.
- 18F with Y-90 is growing fastest because it supports an integrated imaging-to-therapy pathway, helping clinicians improve treatment planning and advance precision-focused radiotheranostic workflows.
Market Expansion Drivers
- Integration of molecular imaging with targeted radionuclide therapy enabling precision oncology treatment selection.
- Expanding clinical validation and regulatory approvals accelerating radiopharmaceutical adoption in oncology centers.
- AI-enabled dosimetry and imaging analytics improving personalized radiotheranostic treatment planning efficiency.
Leading Market Participants
- Top players in the radiotheranostics market include Novartis AG (Switzerland), Bayer AG (Germany), Lantheus Holdings, Inc. (United States), Telix Pharmaceuticals Limited (Australia), POINT Biopharma Global Inc. (United States), Fusion Pharmaceuticals Inc. (Canada), Actinium Pharmaceuticals, Inc. (United States), RadioMedix, Inc. (United States), SHINE Technologies, LLC (United States), NorthStar Medical Radioisotopes, LLC (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 13.6 billion
- 2027 Estimated Market Size: USD 14.63 billion.
- Projected Market Size: USD 32.28 billion by 2036
- Growth Forecast: 9.03% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Europe
- Core Revenue Segment: Targeted Therapeutic (Approach) | Lutetium-177 (Radioisotope) | Oncology (Application)
- Emerging Opportunity Segment: Targeted Therapeutic (Approach) | 18F with Y-90 (Radioisotope) | Oncology (Application)
Market Growth Drivers and Industry Trends
Integration of molecular imaging with targeted radionuclide therapy enabling precision oncology treatment selection
Integration of molecular imaging with targeted radionuclide therapy is strengthening precision treatment approaches in oncology. The radiotheranostics market benefits from this combination because imaging can help identify relevant biological targets and inform therapy selection, enabling treatment strategies to be more closely aligned with the characteristics of individual patients and their tumors.
Expanding clinical validation and regulatory approvals accelerating radiopharmaceutical adoption in oncology centers
Greater clinical validation and regulatory approvals are helping establish radiopharmaceutical approaches within oncology care pathways. As evidence supporting their clinical application expands, the radiotheranostics market is gaining opportunities for adoption across oncology centers, where healthcare providers can incorporate validated radiopharmaceutical treatments into targeted cancer management practices.
AI-enabled dosimetry and imaging analytics improving personalized radiotheranostic treatment planning efficiency
AI-enabled dosimetry and imaging analytics are improving the ability to analyze patient-specific information during treatment planning. For the radiotheranostics market, these capabilities can streamline interpretation and dose planning while supporting more personalized treatment workflows, helping oncology teams manage imaging and therapeutic information with greater operational efficiency.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Integration of molecular imaging with targeted radionuclide therapy enabling precision oncology treatment selection | 2.50% | High | North America, Europe | Medium | Mid Term |
| Expanding clinical validation and regulatory approvals accelerating radiopharmaceutical adoption in oncology centers | 2.20% | High | North America, Europe | Medium | Near Term |
| AI-enabled dosimetry and imaging analytics improving personalized radiotheranostic treatment planning efficiency | 1.80% | Moderate | North America, Europe | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of the radiotheranostics market, accounting for 54.23% share in 2026, supported by advanced nuclear medicine infrastructure, strong oncology care capabilities, and established access to sophisticated diagnostic and therapeutic technologies. The region's healthcare system supports the integration of radiopharmaceutical-based imaging with targeted treatments, enabling more personalized approaches to cancer management. Increasing interest in precision oncology and the development of theranostic strategies that combine disease identification with targeted therapy are strengthening clinical demand. In addition, specialized medical expertise, research activity, and expanding adoption of advanced cancer diagnostics provide a favorable environment for the continued development of radiotheranostics.
Europe (Fastest-Growing Region)
Europe is the fastest-growing region, supported by increasing emphasis on personalized cancer care, improving nuclear medicine infrastructure, and growing clinical interest in targeted radiopharmaceutical therapies. Healthcare systems across the region are placing greater focus on treatment approaches that can improve patient selection and therapeutic precision, creating opportunities for integrated diagnostic and treatment solutions. Expanding capabilities in radiopharmaceutical production, imaging, and specialized clinical services are also improving the ecosystem required for radiotheranostics adoption. Furthermore, growing awareness of precision medicine and efforts to strengthen cancer treatment pathways are encouraging healthcare providers to incorporate advanced theranostic approaches into oncology care.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Oncology IntegrationGermany is advancing radiotheranostics through established nuclear medicine expertise and coordinated hospital networks. Organizations in Germany emphasize standardized clinical workflows, reliable isotope availability, and expanded access to personalized oncology treatments.
France 🇫🇷
Nuclear Medicine ExpansionFrance continues integrating radiotheranostics into comprehensive cancer treatment programs through specialized nuclear medicine facilities. Healthcare organizations in France focus on clinical collaboration, radiopharmaceutical access, and optimized patient selection for targeted therapies.
Italy 🇮🇹
Specialized Care NetworksItaly is expanding radiotheranostics through specialized oncology and nuclear medicine centers that support personalized treatment pathways. Institutions across Italy prioritize clinician expertise, coordinated diagnostics, and improved infrastructure for targeted radiopharmaceutical therapies.
Japan 🇯🇵
Advanced Imaging AdoptionJapan integrates radiotheranostics with sophisticated diagnostic imaging capabilities to improve treatment planning and patient management. Healthcare institutions in Japan prioritize high-quality imaging infrastructure, regulatory compliance, and precision-based therapeutic applications.
South Korea 🇰🇷
Isotope Production FocusSouth Korea is strengthening radiotheranostics by expanding domestic radiopharmaceutical production and specialized oncology services. Medical providers in South Korea invest in modern imaging systems and collaborative clinical programs to support personalized cancer treatment approaches.
United States 🇺🇸
Clinical Translation HubThe U.S. radiotheranostics market is supported by expanding clinical research, specialized treatment centers, and investments in targeted radiopharmaceutical development. Healthcare providers across the U.S. continue strengthening isotope supply, imaging integration, and multidisciplinary cancer care pathways.
Segment Leadership and Growth Trends
Radiotheranostics Market Share (%), by Approach, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportApproach Segment Analysis: Targeted Therapeutic (Largest & Fastest-Growing Segment)
The targeted therapeutic segment led the radiotheranostics market and represented the largest share of 64.43% in 2026, while also emerging as the fastest-growing segment. Its position is supported by the ability to deliver therapeutic radiation more selectively toward disease-associated targets, helping improve treatment precision while limiting unnecessary exposure to surrounding healthy tissues. The approach also aligns closely with personalized medicine by enabling treatment strategies based on specific biological characteristics identified through diagnostic imaging, strengthening its relevance in precision oncology and supporting continued clinical adoption.
Radioisotope Segment Analysis: Lutetium-177 (Largest Segment) vs 18F with Y-90 (Fastest-Growing Segment)
Lutetium-177 held the largest share of the radiotheranostics market at 37.76% in 2026, supported by its suitability for targeted radioligand therapies and its ability to combine therapeutic radiation with imaging capabilities. Its favorable application across precision cancer treatment has strengthened its role in radiotheranostic approaches, particularly where accurate targeting and treatment monitoring are important. Continued interest in personalized cancer care and targeted radionuclide therapy further reinforces the position of lutetium-177 within the radioisotope landscape.
The 18F with Y-90 segment is projected to advance at the fastest pace as healthcare providers increasingly seek complementary diagnostic and therapeutic capabilities within personalized treatment pathways. The combination can support imaging-based disease assessment alongside therapeutic applications, helping clinicians improve treatment planning and monitoring. Growing interest in integrated radiotheranostic strategies, together with advances in molecular targeting and precision medicine, is creating favorable conditions for wider adoption of this segment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Approach | Targeted Therapeutic, Targeted Diagnostic | Targeted Therapeutic | Targeted Therapeutic |
| Radioisotope | Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, Others | Lutetium-177 | 18F with Y-90 |
| Application | Oncology, Non-oncology | Oncology | Oncology |
Competitive Landscape and Market Positioning
Major players in the radiotheranostics market:
1. Novartis AG (Switzerland)
2. Bayer AG (Germany)
3. Lantheus Holdings Inc. (United States)
4. Telix Pharmaceuticals Limited (Australia)
5. POINT Biopharma Global Inc. (United States)
6. Fusion Pharmaceuticals Inc. (Canada)
7. Actinium Pharmaceuticals Inc. (United States)
8. RadioMedix Inc. (United States)
9. SHINE Technologies LLC (United States)
10. NorthStar Medical Radioisotopes LLC (United States)
Advancements in targeted diagnostic and therapeutic integration are accelerating development in the radiotheranostics market. Strong research pipelines are enabling precision-focused treatment approaches that combine imaging and therapy capabilities. Collaborative research efforts are supporting faster clinical translation of emerging solutions. New therapeutic introductions are increasingly centered on improving treatment specificity and patient outcome optimization.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Novartis AG (Switzerland) | |||||||
| Bayer AG (Germany) | |||||||
| Lantheus Holdings Inc. (United States) | |||||||
| Telix Pharmaceuticals Limited (Australia) | |||||||
| POINT Biopharma Global Inc. (United States) | |||||||
| Fusion Pharmaceuticals Inc. (Canada) | |||||||
| Actinium Pharmaceuticals Inc. (United States) | |||||||
| RadioMedix Inc. (United States) | |||||||
| SHINE Technologies LLC (United States) | |||||||
| NorthStar Medical Radioisotopes LLC (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| NUCLIDIUM | Mar-26 | NUCLIDIUM completed a CHF 26.4 million Series B extension, bringing total Series B funding to CHF 105 million. The capital is allocated to advance clinical development of its NU101 and NU201 radiotheranostic programs targeting metastatic castration-resistant prostate cancer and metastatic breast cancer, reinforcing its position in targeted nuclear medicine oncology pipelines and accelerating late-stage translational development. |
| Sarvodaya Healthcare; Oncidium Foundation | Mar-26 | Sarvodaya Healthcare partnered with the Oncidium Foundation to introduce radiotheranostics-based nuclear therapy services for cancer treatment. The collaboration focuses on implementing precision-guided radiotheranostic approaches to improve treatment personalization and clinical outcomes, expanding access to targeted nuclear medicine therapies within oncology care delivery systems. |
| Actinium Pharmaceuticals | Mar-25 | Actinium Pharmaceuticals advanced development of its ATNM-400 Actinium-225 antibody radioconjugate, demonstrating strong preclinical efficacy across multiple solid tumor models. The progress strengthens the company’s targeted alpha-emitter platform strategy and supports expansion of its radiotheranostic pipeline with potential broad oncology applicability across solid tumor indications. |
| SHINE Technologies | Oct-24 | SHINE Technologies advanced isotope production and collaborative preclinical capabilities supporting radiotheranostics development. The initiative strengthens its role as a critical upstream supplier of medical isotopes, enhancing reliability of supply chains for diagnostic and therapeutic nuclear medicine applications and enabling downstream innovation across radiotheranostic pipelines. |
| Sanofi; Orano Med | Oct-24 | Sanofi partnered with Orano Med to advance next-generation radioligand therapies for rare cancers. The collaboration combines oncology and targeted alpha therapy expertise to accelerate development of radiotheranostic treatment approaches, supporting pipeline expansion in precision nuclear medicine for difficult-to-treat cancer indications. |
| Telix Pharmaceuticals Limited | Jul-24 | Telix Pharmaceuticals progressed late-stage development and global rollout of PSMA-targeted imaging agents while advancing therapeutic candidates aligned with radiotheranostic care pathways. The company emphasized diagnostics-led commercialization strategies, positioning imaging agents as clinical entry points to support broader adoption of integrated diagnostic-therapeutic nuclear medicine platforms. |
| Lantheus | Jun-24 | Lantheus acquired global rights to 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2 radiopharmaceutical pairs from Life Molecular Imaging. The acquisition strengthens its radiotheranostics portfolio by integrating complementary diagnostic and therapeutic agents targeting prostate and breast cancer, enhancing its position in clinically advanced radiotheranostic development. |
| Ariceum Therapeutics | Jan-24 | Ariceum Therapeutics submitted an application to the UK MHRA to initiate a Phase 1 clinical trial of 123I-ATT001 in recurrent glioblastoma. The development advances early-stage radiotheranostic evaluation in central nervous system oncology, expanding the application scope of targeted radiopharmaceutical therapies in aggressive tumor indications. |
| Telix Pharmaceuticals Limited; Merck KGaA | Jul-23 | Telix Pharmaceuticals initiated a Phase I trial of TLX250 in combination with Merck KGaA’s peposertib for patients with solid tumors. The study evaluates combination therapy integrating targeted radiation with DNA damage response inhibition, advancing clinical exploration of synergistic radiotheranostic and oncology treatment approaches. |
| Novartis AG | Dec-22 | Novartis AG received European Commission approval for Pluvicto (lutetium Lu-177 vipivotide tetraxetan) combined with androgen deprivation therapy for metastatic castration-resistant prostate cancer. The approval establishes regulatory validation for radioligand therapy in advanced prostate cancer, reinforcing commercialization of targeted radiotheranostic treatment pathways in Europe. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Radiotheranostics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Target Biomarker | PSMA, Somatostatin Receptors, HER2, FAP, Other Biomarkers |
| Treatment Line | First-Line Therapy, Second-Line Therapy, Third-Line and Later Therapy, Maintenance/Consolidation Therapy |
| Care Setting | Academic & Research Hospitals, Specialty Hospitals, Community Hospitals, Specialized Nuclear Medicine Centers |
Radiotheranostics Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Radioisotope Supply Chain Resilience Assessment |
|
| Hospital and Nuclear Medicine Center Adoption Landscape |
|
| Strategic Partnership Opportunity Assessment Across the Care Continuum |
|
Need a different cut of the data?
Request Custom ResearchHow large is the radiotheranostics market?
What is the expected industry size of radiotheranostics by 2036?
How is the integration of diagnostic imaging and targeted therapy influencing adoption in radiotheranostics?
What role is regulatory progress and clinical validation playing in expanding radiotheranostics uptake?
Why does the targeted therapeutic approach lead the radiotheranostics market?
Why is 18F with Y-90 the fastest-growing radioisotope segment in the radiotheranostics market?
Why does North America dominate the radiotheranostics market?
What is fueling radiotheranostics market growth in Europe?
Who holds a significant market share in the radiotheranostics landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization